---
title: Chemotherapy Response Score (CRS) Overview
url: https://www.emergentmind.com/topics/chemotherapy-response-score-crs
type: topic
---

# Chemotherapy Response Score (CRS) Overview

The Chemotherapy Response Score (CRS) is a three-tier histopathological metric designed to evaluate tumor response in omental specimens following neoadjuvant chemotherapy (NACT) for high-grade serous ovarian carcinoma (HGSOC). The score stratifies tumors based on the degree of residual disease and fibro-inflammatory response, and has been operationalized as a key clinical endpoint in multiple radiomics and predictive modeling studies employing pre- and post-NACT computed tomography (CT) data. Recent research couples CRS with advanced radiomics and automated feature robustness assessment, enabling the development of reliable machine learning models for non-invasive chemotherapy response prediction [2601.08455].

## 1. Definition and Clinical Basis of Chemotherapy Response Score

The CRS metric, as specified by Böhm et al., partitions post-NACT omental tumor specimens into distinct response strata, emphasizing histopathological characterization:

| CRS Tier | Histopathologic Criteria                                                                                           |
|----------|-------------------------------------------------------------------------------------------------------------------|
| CRS 1    | Abundant residual tumor with no or minimal response                                                               |
| CRS 2    | Appreciable fibro-inflammatory response but significant viable tumor remains                                       |
| CRS 3    | Complete or near-complete response: no tumor or only minimal (<2 mm) residual tumor nests                         |

In predictive model development, CRS 1–2 are commonly grouped as "non-complete response," while CRS 3 represents "complete response." This dichotomization provides a clinically actionable endpoint for assessing efficacy of NACT and for guiding post-surgical therapy selection [2601.08455].

## 2. Radiomics Pipeline for CRS Prediction

Radiomics analysis supporting CRS prediction is predicated on a standardized pipeline comprising image acquisition, lesion segmentation, feature extraction, and robust feature selection:

- **Image Acquisition**: Pre- and post-NACT contrast-enhanced abdominopelvic CT scans from institutions such as Cambridge and Barts, adhering to standard clinical protocols.
- **Image Pre-processing**:
  - Lesion segmentation is executed semi-automatically (Microsoft InnerEye), with radiologist oversight.
  - Intensity discretization employs a fixed bin width of 4 Hounsfield Units; no additional intensity normalization or resampling is performed.
- **Region of Interest (ROI) Specification**:
  - Lesions are labeled by anatomical site (omental, pelvic).
  - Two pooling strategies: "largest lesion only" and "merged" (all lesions combined).
  - Peripheral rim ROIs (6 mm) are generated for rim radiomics in CRS models.
- **Feature Extraction**:
  - 102 features per ROI derived with Pyradiomics v3.0.1, spanning shape descriptors (e.g., sphericity, surface area), first-order statistics (mean, entropy, skewness, kurtosis), and multiple texture matrices (GLCM, GLRLM, GLSZM, GLDM, NGTDM).

This pipeline underpins the extraction of quantifiable markers potentially insensitive to reader or institution-specific protocol differences [2601.08455].

## 3. Robustness Assessment and Feature Selection

A distinguishing aspect of recent CRS prediction work is the explicit modeling of inter-observer segmentation variability via automated random perturbation of VOIs (volumes of interest):

- **Robustness Modeling**: Randomized segmentation, applying small geometric perturbations, mimics plausible variability between human annotators.
- **Intraclass Correlation Coefficient (ICC) Computation**: For each radiomics feature $f$, the ICC is computed between original and perturbed VOIs using the two-way consistency model (single measurement):
  $$
  \mathrm{ICC}(f) = \frac{\sigma^2_{\text{between}}}{\sigma^2_{\text{between}} + \sigma^2_{\text{within}}}
  $$
- **ICC Interpretation**:
  - ICC ≥ 0.90: "excellent"
  - ICC 0.70–0.90: "moderate"
  - ICC < 0.70: "poor"

Feature selection methodologies include:
- **Filtering**: Univariate Feature Selection (UFS) within 5-fold stratified CV removes highly correlated/non-informative features.
- **Feature Selection Algorithms**: F-score, Relief, Mutual Information, Gini importance, LASSO, Genetic Algorithm (GA), Sequential Forward/Backward Search (SFS/SBS), Recursive Feature Elimination (RFE).
- **PREDICTIVE&ROBUST Approaches**:
  1. Fully robust: Pre-filter features with ICC > 0.80.
  2. Semi-robust: At each iteration, ≥ 80% of features must have ICC > 0.80.
  3. Weighted robustness: Composite relevance-robustness score $s' = (1-w) s + w c$, with $w=0.5$ (where $s$ is predictive relevance, $c$ is mean ICC).

These steps maximize model stability and reliability by deprioritizing features sensitive to segmentation noise [2601.08455].

## 4. Machine Learning Models for CRS Prediction

Modeling to predict CRS employs classical linear classifiers, with feature selection strategies that incorporate robustness constraints explicitly:

- **Classifiers**:
  - Logistic Regression (LR)
  - Linear Discriminant Analysis (LDA)
- **Training Strategy**:
  - 5-fold stratified cross-validation on the training set (OV04) to optimize FS + classifier combinations, using AUC as the selection criterion.
  - No additional hyperparameter grid search beyond intrinsic LASSO/GA settings.
- **Robustness-Constrained Feature Sets**: Only feature sets selected per the PREDICTIVE&ROBUST criteria are used for final model training.

The integration of linear models with rigorously filtered and robustness-weighted feature sets aims to provide both interpretability and reproducibility, essential for biomarker development in translational imaging [2601.08455].

## 5. Performance Evaluation and Lesion-Specific Insights

The benchmark for CRS model evaluation is external validation using an independent cohort (BARTS):

| Lesion Site & ROI Strategy              | CRS AUC | G-Mean | Sensitivity | Specificity |
|-----------------------------------------|---------|--------|-------------|-------------|
| Omental (merged, weighted, SFS+LDA)     | 0.77    | 0.72   | 0.56        | 0.92        |
| Omental (rim radiomics only)            | 0.74    | —      | —           | —           |
| Pelvic (rim radiomics only)             | 0.42    | —      | —           | —           |

- **Omental Lesion Dominance**: Omental lesions consistently provided the highest AUC (0.77 vs. 0.62–0.68 for pelvic/all), with a favorable balance of sensitivity and specificity.
- **Robustness of Omental Features**: A greater proportion of omental features exhibited "excellent" ICC, indicating superior measurement stability under segmentation perturbation.
- **Rim Radiomics**: For omental disease, rim-based features matched whole-ROI performance (AUC = 0.74), but rim-only pelvics showed marked performance degradation (AUC = 0.42).
- **Interpretation**: These results suggest that omental tumor imaging yields more reproducible texture and shape signals that correlate strongly with histopathologic treatment response, and that model robustness is lesion site-dependent.

No confidence intervals were reported for these metrics [2601.08455].

## 6. Clinical Implications, Limitations, and Prospects

Incorporating segmentation robustness in feature selection demonstrably improves the reliability of radiomics-derived CRS predictors, thereby supporting clinical deployment for stratifying patients based on predicted NACT response:

- **Clinical Validity**: Robust radiomics models may triage patients unlikely to benefit from NACT, guiding more effective personalized therapy.
- **Methodological Constraints**:
  - Semi-manual segmentation is labor-intensive and limits scalability.
  - CT acquisition variability (e.g., slice thickness, scanner heterogeneity) was not comprehensively harmonized.
  - No prospective, real-time deployment or validation has been performed.
- **Future Directions**:
  - Automating lesion delineation via deep learning to enable on-the-fly generation of perturbed VOIs for robustness modeling.
  - Integration of real-time radiomics workflows in multidisciplinary cancer care settings.
  - Extension to multi-parametric or "habitat" approaches to enhance model generalizability across institutions.

*A plausible implication is that the described framework—by simulating inter-observer segmentation variability and prioritizing robust features—lays the foundation for reproducible CT-based biomarkers, facilitating objective and individualized patient management in ovarian cancer*. The strategy outlined offers a blueprint for future studies targeting robust predictive radiomics in other cancer types and contexts [2601.08455].

Source: https://www.emergentmind.com/topics/chemotherapy-response-score-crs